Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

"Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical ...

What Happened: file made a significant move by purchasing 1,565 shares of Eli Lilly as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...